Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.
Ocular Therapeutix, Inc. will present 12-month data from the U.S.-based phase 1 trial of OTX-TKI at the Clinical Trials at the Summit Annual Meeting. The meeting is being held on June 10, 2023 in Park City, Utah. Ocular Therapeutix is also sponsoring a presentation discussing the Company's proprietary bioresorbable hydrogel-based formulation technology and retina focused clinical programs. A conference call discussing the 12-month data from the U.S.-based Phase 1 clinical trial of OTX-TKI presented at the Clinical Trials at the Summit will be hosted by the Ocular Therapeutix management team on Monday, June 12th at 8:30 am ET.
“We look forward to presenting the 12-month data update from our U.S.-based trial evaluating OTX-TKI for the treatment of wet AMD,” stated Rabia Gurses Ozden, MD, Chief Medical Officer of Ocular Therapeutix in the press release. “Our most recent update at 10-months observed that CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects with a 92% reduction in treatment burden in the OTX-TKI arm. This new data will include additional information regarding the pharmacodynamics of OTX-TKI at month 12.”
Presentations at Clinical Trials at the Summit:
12-Month Update on Randomized, Controlled, Trial of OTX-TKI (Axitinib Intravitreal Implant) for the Treatment of Wet AMD
Challenges of Bringing Novel Treatment Options to the Market
Ocular Therapeutix: Transforming Ophthalmic Care with Innovative Therapies